6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]-pyridine-3-acetic acid

We are 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]-pyridine-3-acetic acid CAS:189005-44-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 6-Methyl-2-(4-methylphenyl)imidazo[1,2-a]-pyridine-3-acetic acid
CAS.NO: 189005-44-5
Synonyms:
[6-methyl-2-(4-methyl-phenyl)-imidazo[1,2-a]pyridine-3-yl]-acetic acid
6-methyl-2-(4-methylphenyl)-imidazo-[1,2-a]-pyridine
2-(6-methyl-2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)acetic acid
2-(4-methylphenyl)-6-methylimidazo(1,2-a)pyridine-3-acetic acid
2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetic acid

Molecular Formula:C17H16N2O2
Molecular Weight:280.321

Physical and Chemical Properties:
Density: 1.22g/cm3
Boiling point: /
Melting point:243-245ºC
Flash point:/
Refractive index: 1.631

Specification:
Appearance: White Powder
Purity:≥99%

 

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Zolpidem  CAS: 82626-48-0
Intermediates of Zolpidem tartrate  CAS:99294-93-6

Related News: This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.(4S)-1-methyl-2,6-dioxo-1,3-diazinane-4-carboxylic acid At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.53596-81-9 At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.N6-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)adenosine The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.At the same time, due to the relatively late development of the bulk drug business in China, most of the established bulk drug companies are currently in the field of commonly used generic drug bulk drugs. Stand up.